PHVS
Pharvaris N.V. [PHVS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
PHVS Stock Summary
Top 10 Correlated ETFs
PHVS
Top 10 Correlated Stocks
PHVS
In the News
PHVS Financial details
Company Rating
-
Market Cap
894.76M
Income
-84.69M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
70
Optionable
No
Shortable
Yes
Earnings
06 May 2024
P/E
-11.31
Forward P/E
-
PEG
-0.98
P/S
-
P/B
6.26
P/C
-
P/FCF
-10.66
Quick Ratio
9.85
Current Ratio
10.46
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-3.04
EPS next Y
-
EPS next Q
-
EPS this Y
60.99%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-7.94%
-
-
-
-
SMA20
-18.75%
SMA50
-27.78%
SMA100
-38.1%
Inst Own
-
Inst Trans
-
ROA
-50%
ROE
-56%
ROC
-0.48%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
7.93-33.0
52W High
-59.95%
52W Low
+88.79%
RSI
35
Rel Volume
0.13
Avg Volume
110.2K
Volume
14.14K
Perf Week
0.04%
Perf Month
-11.84%
Perf Quarter
-40.9%
Perf Half Y
-35.72%
-
-
-
-
Beta
-3.113
-
-
Volatility
0.46%, 1.5%
Prev Close
4.71%
Price
13.215
Change
8.77%
Company Profile
- Volume Average 110.2K
- Market Capitalization 894.76M
- Employee 70
- CEO Mr. Berndt Axel Edvard Modig CPA, M.B.A.
- Headquarters Leiden,NL
- IPO Date 2021-02-05
-
Website
https://pharvaris.com 
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
